secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2026-05-12T20:01:42+00:00
Accession:  0001108205-26-000059
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q1 net loss $24.2M, no revenue; cash $15M; clinical milestones ahead
--------------------------------------------------------------------------

- Net loss of $24.2M ($1.25 per share) vs $10.6M loss in Q1 2025; EPS unchanged due to higher share count.
- No revenue in Q1 2026 after sale of Erivedge royalties in Q4 2025; Q1 2025 had $2.4M royalty revenue.
- Cash and equivalents $15.0M as of Mar 31; expects runway into H2 2027 contingent on $20.2M Series B warrant exercise.
- Closed $80.8M private placement in Jan 2026; initial $20.2M received; warrants exercisable at $0.75 per share.
- TakeAim CLL combination trial with zanubrutinib expects dosing of 5th patient mid-2026; PCNSL data in 1H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820526000059/0001108205-26-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820526000059/cris-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001108205-26-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer